Which targets are overheated? — Convoke Insights

·

29 min read Original article ↗

Target crowding is a chronic affliction of the biotech industry; there’s an ongoing tragedy of the commons where too many resources are competing for the same small slice of patient biology. 77% of clinical-stage drugs are going after the most popular 20% of targets (425 of 2,122), and 31% after just the top 2%.

20% of targets attract 77% of clinical-stage drugs

20% of targets attract 77% of clinical-stage drugsTargets are ordered by their number of distinct recorded clinical-stage drugs, highest first; ties use target ID. Drug shares use the union of drug IDs across selected targets. Multispecifics and indication expansions do not multiply drug counts. Includes every activity status and parent-target rollups. Both axes run linearly from 0% to 100%. Percentage cutoffs round target counts up to the next whole target.Share of clinical-stage drugs0%25%50%75%100%0%20%40%60%80%100%Share of targetsMost targeted first → least targetedTop 2% · 43 targets · 3,943 drugs (30.6%)Top 2% of targets31% of drugs43 targetsTop 20% · 425 targets · 9,889 drugs (76.8%)Top 20% of targets77% of drugs425 targets

Source: Convoke pipeline data · snapshot 2026-11-11.

In some cases it can be rational to go after a crowded target if you think you have a differentiated approach to improve the modulation of known, validated biology (e.g., longer dosing enabled by PCSK9 siRNAs), or the market is simply so large that it can support many entrants (e.g., GLP-1 receptor agonists in obesity). Yet in some cases we see companies piling into novel targets before they’ve been validated by clinical efficacy or market demand.

Prior analyses have focused on simple counts of active drug programs by target as an indicator of crowdedness. We were interested in adding another layer: How rapidly do targets accumulate new clinical programs? And how does the rate of accumulation of new drugs against a target track with what we'd expect relative to the level of validation?

A typical target attracts new clinical-stage molecules at a steady cadence of about 0.3 per year after its first clinical entry, with a modest increase in annual starts over time as development activity matures. However, for some targets we see new program starts lag clinical and regulatory validation milestones, and for other targets new clinical starts race ahead of clinical validation. For instance, PCSK9 had significant genetic support and development activity was intense even before clinical and regulatory validation. Other targets only become hot after substantial evidence has accumulated, or never become hot at all despite solid biological rationale.

Most targets accumulate new clinical-stage drugs at a steady cadence

Cumulative clinical starts over the first 20 yearsCumulative clinical startsdistinct drugs per target02040600n=7875n=78710n=78715n=78720n=525By year 0 · PCSK9: 2 cumulative startsBy year 1 · PCSK9: 5 cumulative startsBy year 2 · PCSK9: 8 cumulative startsBy year 3 · PCSK9: 11 cumulative startsBy year 4 · PCSK9: 11 cumulative startsBy year 5 · PCSK9: 12 cumulative startsBy year 6 · PCSK9: 15 cumulative startsBy year 7 · PCSK9: 17 cumulative startsBy year 8 · PCSK9: 19 cumulative startsBy year 9 · PCSK9: 23 cumulative startsBy year 10 · PCSK9: 24 cumulative startsBy year 11 · PCSK9: 25 cumulative startsBy year 12 · PCSK9: 26 cumulative startsBy year 13 · PCSK9: 28 cumulative startsBy year 14 · PCSK9: 33 cumulative startsBy year 15 · PCSK9: 36 cumulative startsBy year 16 · PCSK9: 44 cumulative startsBy year 17 · PCSK9: 52 cumulative starts · partial year through 2026-11-11PCSK952 startsBy year 0 · RANKL: 1 cumulative startsBy year 1 · RANKL: 1 cumulative startsBy year 2 · RANKL: 1 cumulative startsBy year 3 · RANKL: 1 cumulative startsBy year 4 · RANKL: 1 cumulative startsBy year 5 · RANKL: 1 cumulative startsBy year 6 · RANKL: 1 cumulative startsBy year 7 · RANKL: 1 cumulative startsBy year 8 · RANKL: 2 cumulative startsBy year 9 · RANKL: 2 cumulative startsBy year 10 · RANKL: 2 cumulative startsBy year 11 · RANKL: 2 cumulative startsBy year 12 · RANKL: 2 cumulative startsBy year 13 · RANKL: 2 cumulative startsBy year 14 · RANKL: 2 cumulative startsBy year 15 · RANKL: 2 cumulative startsBy year 16 · RANKL: 3 cumulative startsBy year 17 · RANKL: 7 cumulative startsBy year 18 · RANKL: 11 cumulative startsBy year 19 · RANKL: 14 cumulative startsBy year 20 · RANKL: 14 cumulative startsRANKL14 startsBy year 0 · FGF23: 1 cumulative startsBy year 1 · FGF23: 1 cumulative startsBy year 2 · FGF23: 1 cumulative startsBy year 3 · FGF23: 1 cumulative startsBy year 4 · FGF23: 1 cumulative startsBy year 5 · FGF23: 1 cumulative startsBy year 6 · FGF23: 1 cumulative startsBy year 7 · FGF23: 1 cumulative startsBy year 8 · FGF23: 1 cumulative startsBy year 9 · FGF23: 1 cumulative startsBy year 10 · FGF23: 1 cumulative startsBy year 11 · FGF23: 1 cumulative startsBy year 12 · FGF23: 1 cumulative startsBy year 13 · FGF23: 1 cumulative startsBy year 14 · FGF23: 1 cumulative startsBy year 15 · FGF23: 1 cumulative startsBy year 16 · FGF23: 2 cumulative startsBy year 17 · FGF23: 2 cumulative startsBy year 18 · FGF23: 2 cumulative starts · partial year through 2026-11-11FGF232 startsBy year 0 · Typical (all targets): 1.1 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 1 · Typical (all targets): 1.3 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 2 · Typical (all targets): 1.5 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 3 · Typical (all targets): 1.8 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 4 · Typical (all targets): 2.1 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 5 · Typical (all targets): 2.3 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 6 · Typical (all targets): 2.7 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 7 · Typical (all targets): 2.9 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 8 · Typical (all targets): 3.2 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 9 · Typical (all targets): 3.4 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 10 · Typical (all targets): 3.8 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 11 · Typical (all targets): 4.0 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 12 · Typical (all targets): 4.4 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 13 · Typical (all targets): 4.8 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 14 · Typical (all targets): 5.2 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 15 · Typical (all targets): 5.7 cumulative starts · 787 observed targets; 0 with a partial 2026 yearBy year 16 · Typical (all targets): 6.2 cumulative starts · 787 observed targets; 48 with a partial 2026 yearBy year 17 · Typical (all targets): 6.9 cumulative starts · 739 observed targets; 60 with a partial 2026 yearBy year 18 · Typical (all targets): 7.4 cumulative starts · 679 observed targets; 84 with a partial 2026 yearBy year 19 · Typical (all targets): 8.3 cumulative starts · 595 observed targets; 70 with a partial 2026 yearBy year 20 · Typical (all targets): 9.4 cumulative starts · 525 observed targets; 76 with a partial 2026 yearTypical (all targets)9.4 startsYears since target’s first clinical entry

Source: Convoke pipeline data · snapshot 2026-11-11.

Regulatory approval is the most important form of validation, and the US FDA is the most important regulator. We should expect that as drug developers become more confident that a target can support approvable drugs, development activity should increase; we see a modest increase in new clinical entry rates for targets leading up to and after the first approval of a drug against that target. In some cases (e.g., Claudin 18) confidence rises before approval, in others it's not until after the approval that target activity rises substantially.

Clinical entry rates tend to rise near first approval

Four-year rolling mean new drug starts per target-year around first FDA approval recordNew clinical startsdistinct drugs per target per yearFirst FDA approvalBefore approvalAfter approval051015CLDN18 / 18.2 · 0 starts / 4 years = 0.00 per year · years -12 to less than -8 · first FDA record 2024-10-18CLDN18 / 18.2 · 0 starts / 4 years = 0.00 per year · years -11 to less than -7 · first FDA record 2024-10-18CLDN18 / 18.2 · 0 starts / 4 years = 0.00 per year · years -10 to less than -6 · first FDA record 2024-10-18CLDN18 / 18.2 · 1 starts / 4 years = 0.25 per year · years -9 to less than -5 · first FDA record 2024-10-18CLDN18 / 18.2 · 4 starts / 4 years = 1.00 per year · years -8 to less than -4 · first FDA record 2024-10-18CLDN18 / 18.2 · 13 starts / 4 years = 3.25 per year · years -7 to less than -3 · first FDA record 2024-10-18CLDN18 / 18.2 · 32 starts / 4 years = 8.00 per year · years -6 to less than -2 · first FDA record 2024-10-18CLDN18 / 18.2 · 41 starts / 4 years = 10.25 per year · years -5 to less than -1 · first FDA record 2024-10-18CLDN18 / 18.2 · 39 starts / 4 years = 9.75 per year · years -4 to less than 0 · first FDA record 2024-10-18CLDN18 / 18.2 · 36 starts / 4 years = 9.00 per year · years -3 to less than +1 · first FDA record 2024-10-18CLDN18 / 18.2 · 23 starts / 4 years = 5.75 per year · years -2 to less than +2 · first FDA record 2024-10-18GIPR · 1 starts / 4 years = 0.25 per year · years -12 to less than -8 · first FDA record 2022-05-13GIPR · 0 starts / 4 years = 0.00 per year · years -11 to less than -7 · first FDA record 2022-05-13GIPR · 1 starts / 4 years = 0.25 per year · years -10 to less than -6 · first FDA record 2022-05-13GIPR · 2 starts / 4 years = 0.50 per year · years -9 to less than -5 · first FDA record 2022-05-13GIPR · 3 starts / 4 years = 0.75 per year · years -8 to less than -4 · first FDA record 2022-05-13GIPR · 5 starts / 4 years = 1.25 per year · years -7 to less than -3 · first FDA record 2022-05-13GIPR · 5 starts / 4 years = 1.25 per year · years -6 to less than -2 · first FDA record 2022-05-13GIPR · 6 starts / 4 years = 1.50 per year · years -5 to less than -1 · first FDA record 2022-05-13GIPR · 10 starts / 4 years = 2.50 per year · years -4 to less than 0 · first FDA record 2022-05-13GIPR · 9 starts / 4 years = 2.25 per year · years -3 to less than +1 · first FDA record 2022-05-13GIPR · 15 starts / 4 years = 3.75 per year · years -2 to less than +2 · first FDA record 2022-05-13GIPR · 20 starts / 4 years = 5.00 per year · years -1 to less than +3 · first FDA record 2022-05-13GIPR · 19 starts / 4 years = 4.75 per year · years 0 to less than +4 · first FDA record 2022-05-13BTK · 4 starts / 4 years = 1.00 per year · years -4 to less than 0 · first FDA record 2013-11-13BTK · 8 starts / 4 years = 2.00 per year · years -3 to less than +1 · first FDA record 2013-11-13BTK · 7 starts / 4 years = 1.75 per year · years -2 to less than +2 · first FDA record 2013-11-13BTK · 14 starts / 4 years = 3.50 per year · years -1 to less than +3 · first FDA record 2013-11-13BTK · 17 starts / 4 years = 4.25 per year · years 0 to less than +4 · first FDA record 2013-11-13BTK · 15 starts / 4 years = 3.75 per year · years +1 to less than +5 · first FDA record 2013-11-13BTK · 18 starts / 4 years = 4.50 per year · years +2 to less than +6 · first FDA record 2013-11-13BTK · 10 starts / 4 years = 2.50 per year · years +3 to less than +7 · first FDA record 2013-11-13BTK · 12 starts / 4 years = 3.00 per year · years +4 to less than +8 · first FDA record 2013-11-13BTK · 17 starts / 4 years = 4.25 per year · years +5 to less than +9 · first FDA record 2013-11-13BTK · 17 starts / 4 years = 4.25 per year · years +6 to less than +10 · first FDA record 2013-11-13BTK · 18 starts / 4 years = 4.50 per year · years +7 to less than +11 · first FDA record 2013-11-13BTK · 15 starts / 4 years = 3.75 per year · years +8 to less than +12 · first FDA record 2013-11-13Years -12 to less than -8 · mean 0.25 starts/target/year · 29 starts ÷ 116 target-years · 29 targets, including zero-start windowsYears -11 to less than -7 · mean 0.26 starts/target/year · 37 starts ÷ 140 target-years · 35 targets, including zero-start windowsYears -10 to less than -6 · mean 0.33 starts/target/year · 52 starts ÷ 156 target-years · 39 targets, including zero-start windowsYears -9 to less than -5 · mean 0.34 starts/target/year · 61 starts ÷ 180 target-years · 45 targets, including zero-start windowsYears -8 to less than -4 · mean 0.46 starts/target/year · 91 starts ÷ 200 target-years · 50 targets, including zero-start windowsYears -7 to less than -3 · mean 0.56 starts/target/year · 121 starts ÷ 216 target-years · 54 targets, including zero-start windowsYears -6 to less than -2 · mean 0.70 starts/target/year · 151 starts ÷ 216 target-years · 54 targets, including zero-start windowsYears -5 to less than -1 · mean 0.86 starts/target/year · 204 starts ÷ 236 target-years · 59 targets, including zero-start windowsYears -4 to less than 0 · mean 0.94 starts/target/year · 236 starts ÷ 252 target-years · 63 targets, including zero-start windowsYears -3 to less than +1 · mean 1.00 starts/target/year · 259 starts ÷ 260 target-years · 65 targets, including zero-start windowsYears -2 to less than +2 · mean 1.05 starts/target/year · 290 starts ÷ 276 target-years · 69 targets, including zero-start windowsYears -1 to less than +3 · mean 1.16 starts/target/year · 297 starts ÷ 256 target-years · 64 targets, including zero-start windowsYears 0 to less than +4 · mean 1.23 starts/target/year · 310 starts ÷ 252 target-years · 63 targets, including zero-start windowsYears +1 to less than +5 · mean 0.97 starts/target/year · 213 starts ÷ 220 target-years · 55 targets, including zero-start windowsYears +2 to less than +6 · mean 1.09 starts/target/year · 227 starts ÷ 208 target-years · 52 targets, including zero-start windowsYears +3 to less than +7 · mean 1.17 starts/target/year · 220 starts ÷ 188 target-years · 47 targets, including zero-start windowsYears +4 to less than +8 · mean 1.13 starts/target/year · 190 starts ÷ 168 target-years · 42 targets, including zero-start windowsYears +5 to less than +9 · mean 1.37 starts/target/year · 219 starts ÷ 160 target-years · 40 targets, including zero-start windowsYears +6 to less than +10 · mean 1.38 starts/target/year · 199 starts ÷ 144 target-years · 36 targets, including zero-start windowsYears +7 to less than +11 · mean 1.70 starts/target/year · 231 starts ÷ 136 target-years · 34 targets, including zero-start windowsYears +8 to less than +12 · mean 1.30 starts/target/year · 140 starts ÷ 108 target-years · 27 targets, including zero-start windowsCLDN18 / 18.25.75 starts/yearGIPR4.75 starts/yearBTK3.75 starts/yearAll-target mean1.30 starts/year-10-50+5+10Years before / after first FDA approval

Source: Convoke pipeline data · snapshot 2026-11-11.

Heat index

We wanted to look at how crowding relates to the level of validation for a given target. To explore this question we created a novel "heat score" metric that combines an assessment of:

  1. How many active programs against a target
  2. A validation score: How likely the target is to have an approved drug based on development activity and trends in approvals for similar indications based on shared targets

Then we use that validation score to fit a linear regression that gives us a number of expected programs given the level of validation (see methodology below). High heat scores mean targets are “overheated”: there are many active clinical drugs relative what we would expect given their validation score. The top 200 overheated targets are shown in the table below.

Top 200 targets by heat score

Methodology

RankTargetTherapy area
1CD3

Oncology

165+94.4+0.3
2BCMA

ImmunologyHematologyOncology

65+92.3+2.7
3CD19

ImmunologyNephrologyOncology

140+91.4-3.2
44-1BB

Oncology

55+90.5-0.1
5MSLN

Oncology

40+89.6+4.7
6FAP

Oncology

39+89.5+0.8
7EGFR

Oncology

100+89.4+1.6
8PD-1

Oncology

138+88.7-1.6
9CD28

Oncology

28+86.8+3.6
10CD70

Oncology

27+86.7+6.6
11CDK4

Oncology

33+86.5+1.0
12CD40

Oncology

32+86.4+0.5
13CD47

OncologyHematology

35+86.4-0.2
14B7-H3

Oncology

57+86.0+0.8
15GPC3

Oncology

41+86.0-5.3
16KRAS

Oncology

95+85.4-4.8
17PRMT5

Oncology

26+85.3+0.0
18Topoisomerase I

Oncology

74+85.3-0.3
19PD-L1

Oncology

82+85.2+0.3
20NLRP3

NeurologyEndocrinologyCardiovascular

32+84.9+4.4
21IL-15R

Oncology

26+84.4+0.4
22CDK6

Oncology

26+84.0+1.1
23c-Met

Oncology

49+83.7-0.6
24mTOR

OncologyNeurology

32+82.9+1.2
25CEA

Oncology

28+82.4+2.0
26MUC1

Oncology

22+82.3+9.5
27CDH17

Oncology

19+81.7+9.2
28PI3K-alpha

Oncology

26+81.6+0.9
29HER2

Oncology

64+81.6+1.1
30PI3K

Oncology

50+81.0-0.7
31CD73

Oncology

21+80.5-0.3
32PSMA

Oncology

17+80.5+20.2
33CDK2

Oncology

23+80.3+0.1
34STING

Oncology

19+80.2-1.3
35EP4

Oncology

17+79.4-0.7
36DPP4

—

19+79.2+2.3
37A2AR

OncologyNeurology

22+79.0+2.6
38c-Kit

OncologyDermatologyHematology

39+78.8+0.9
39CCR8

Oncology

17+78.8-1.9
40TGF-beta 1

OncologyOrthopedics

18+78.6+0.0
41GR

OncologyNeurology

29+78.5+1.0
42CD7

OncologyHematology

19+78.5-0.5
43SIRPalpha

Oncology

15+78.5-0.0
44IL-2RB

Oncology

20+78.1-0.7
45OX40

OncologyDermatology

18+78.0+2.7
46STAT3

Oncology

18+78.0-1.5
47CLDN6

Oncology

17+77.9-0.0
48TLR4

Infectious diseaseImmunologyOncology

17+77.8+2.4
49LAG-3

Oncology

24+77.8+0.6
50ADRB2

—

25+77.8-2.4
51IRAK4

DermatologyImmunologyHematology

17+77.8+3.9
52AR

OncologyNeurologyEndocrinology

23+77.5+2.0
53ER alpha

OncologyEndocrinology

25+77.1+0.9
54CoREST

OncologyHematology

26+77.1+1.6
55NY-ESO-1

Oncology

17+77.0+2.2
56KRAS G12V

Oncology

15+77.0+7.0
57TLR8

Oncology

22+76.7-3.4
58CTLA-4

Oncology

50+76.6-3.0
59CSF-1R

OncologyPulmonology

23+76.4+1.6
60BTK

OncologyImmunologyNeurology

48+76.3-1.5
61FLT3

OncologyHematology

36+75.5-2.0
62FGFR2

Oncology

25+75.4+2.7
63COX-2

Oncology

35+74.8+0.3
64ILT4

Oncology

13+74.3+4.7
65IL-15

OncologyDermatologyGastroenterology

14+74.0+8.5
66CD22

OncologyHematology

32+73.7+0.6
67DRD2

PsychiatryNeurology

31+73.7+1.8
68VEGF-A

Oncology

48+73.3-0.7
69CAIX

Oncology

23+73.3+5.0
70PPARgamma

GastroenterologyNeurologyCardiovascular

24+73.1+0.8
71AKT1

OncologyHematology

14+73.0+0.0
72HDAC6

OncologyHematologyNeurology

17+73.0+3.4
73GRPR

Oncology

13+72.8+17.0
74TLR7

OncologyInfectious disease

23+72.7-3.8
75TRKA

NeurologyOncology

15+72.6-0.3
76ATR

Oncology

14+72.4+1.7
77CD16a

OncologyHematology

12+72.4+0.1
785-HT2A

PsychiatryNeurology

44+72.1+1.9
79CRBN

OncologyHematologyImmunology

19+72.0+3.7
80TROP2

Oncology

36+72.0+1.0
81INHBE

Endocrinology

12+71.9+52.2
82IGF-1R

OncologyNeurologyEndocrinology

15+71.6+1.8
83ROR1

OncologyHematology

16+71.1+3.0
84Bcl-xL

OncologyHematology

12+71.0+10.0
85JAK1

DermatologyImmunologyOphthalmology

34+70.9+0.8
86Integrin alpha V

Oncology

12+70.7+3.2
87SERT

Neurology

30+70.6+2.1
88VEGFR2

OncologyOphthalmology

37+70.5+0.1
89BRAF

OncologyHematology

16+70.5-4.6
90JAK2

HematologyDermatologyOncology

22+70.2+0.5
91EpCAM

Oncology

15+69.8+7.0
92POLQ

Oncology

11+69.7+3.3
93HDAC1

OncologyHematology

17+69.6+0.3
94AXL

Oncology

19+69.5-0.5
95CD3E

Oncology

12+69.5-0.9
96CB1

NeurologyPsychiatryEndocrinology

18+69.3+0.9
97KIF18A

Oncology

10+69.2+16.8
98DHODH

OncologyInfectious diseaseHematology

13+69.1-0.1
99BRD4

OncologyHematology

13+69.1-1.9
100CD8A

Oncology

10+68.9+0.0
101HPK1

Oncology

13+68.8+0.7
102Bcl-2

OncologyHematology

19+68.7+2.2
103MC1R

OncologyImmunologyNephrology

13+68.6+0.8
104S1P1

DermatologyImmunologyNeurology

19+68.5-8.7
105PRAME

Oncology

12+68.5+4.3
1065T4

Oncology

11+68.4+2.7
107beta-tubulin

OncologyInfectious disease

18+68.4-0.5
108GLP-1R

CardiovascularNeurologyEndocrinology

48+68.3-3.7
109TRPV1

NeurologyPsychiatryEndocrinology

14+68.2+0.2
110FGFR1

Oncology

17+68.1+0.0
111PPAR-alpha

GastroenterologyNeurologyOncology

19+67.8-0.4
112TLR9

OncologyInfectious disease

16+67.8+0.0
113Survivin

Oncology

11+67.8+0.2
114CD38

HematologyImmunologyOncology

15+67.6+7.9
115Tissue Factor

OncologyInfectious disease

13+67.4+3.0
116TfR

NeurologyOncology

11+67.2+7.9
117SSTR2

Oncology

21+67.0-2.7
118TIM-3

OncologyHematology

11+67.0-1.2
119CD33

OncologyHematology

19+67.0+19.5
120p53

Oncology

11+66.9-0.3
121TUBB

Oncology

18+66.8-0.9
122IL-2

Oncology

14+66.7+2.1
123IL-1RAcP

DermatologyImmunologyOncology

10+66.6+5.9
124SHP2

Oncology

11+66.6-2.5
125TrkB

NeurologyOncology

11+66.5+0.1
126TIGIT

Oncology

27+66.0-4.3
127TRPA1

NeurologyGastroenterology

10+66.0-0.1
128Beta-catenin

OncologyOrthopedics

10+65.9+2.9
129CLL-1

OncologyHematology

9+65.9+16.4
130HER3

Oncology

34+65.7-0.8
131CDK9

OncologyHematology

10+65.5-0.0
132WRN

Oncology

11+65.3+10.6
133Menin

HematologyOncologyEndocrinology

10+65.3+3.0
134Integrin beta 6

Oncology

9+65.3+19.1
135IL-6

ImmunologyEndocrinologyOphthalmology

17+64.9-1.6
136CB2

NeurologyEndocrinologyPsychiatry

13+64.9+0.5
137ABL1

OncologyNeurologyHematology

13+64.8+0.4
138MAGE-A4

Oncology

9+64.7+5.2
139hypocretin receptor 2

PulmonologyNeurologyPsychiatry

12+64.7+27.9
140PARP1

Oncology

32+64.5+5.1
141Nectin-4

Oncology

25+64.4-9.6
142PI3K-delta

OncologyHematology

19+64.3+0.2
143WEE1

Oncology

12+64.3-6.7
144ERK2

OncologyHematology

9+64.3-3.6
145GC-C

Oncology

9+64.2+5.0
146p300

OncologyHematology

9+64.0-2.6
147CD123

OncologyHematology

21+63.9+4.9
148CBP

OncologyHematology

9+63.6-2.6
149Aiolos

OncologyHematologyImmunology

14+63.6+1.5
150Ikaros

OncologyHematologyImmunology

14+63.6+1.5
151Plasminogen

Infectious diseaseWomen’s healthCardiovascular

12+63.2+2.6
152RET

Oncology

15+63.2+0.4
153AhR

Gastroenterology

12+63.1+1.9
154APRIL

ImmunologyNephrologyNeurology

11+63.1+13.5
155NRF2

OncologyOrthopedics

11+62.8+5.2
156A2BR

Oncology

8+62.5+5.3
157PDGFR-beta

OncologyPulmonologyHematology

14+62.4-2.9
158LILRB1

Oncology

8+62.4+5.3
159OX40L

DermatologyGastroenterology

14+61.9+12.2
160PDGFR-alpha

Oncology

15+61.8-1.4
161TYK

DermatologyGastroenterologyImmunology

33+61.7+9.2
162PKC

OncologyDermatologyEndocrinology

11+61.6+5.4
163MALT1

OncologyHematology

8+61.6+3.2
164CLDN18

Oncology

53+61.4+0.3
165CHK1

Oncology

8+61.4+0.0
166DRD3

PsychiatryNeurology

19+61.2+6.2
167CD39

Oncology

8+61.2-1.1
168CD5

OncologyHematology

9+61.1+15.0
169GDF15

EndocrinologyOncology

9+61.0+5.2
170Tau protein

Neurology

18+61.0-8.0
171WT1

Oncology

8+60.9+0.5
172TNFR2

Oncology

8+60.8-0.0
173FGFR3

OncologyOrthopedics

18+60.4-0.8
174SYK

ImmunologyOncologyHematology

11+60.2-3.2
175EP2

Oncology

8+60.2-0.1
176CD32B

HematologyImmunologyOncology

8+59.6+5.9
177ALPP

Oncology

7+59.3+32.5
178TGFBR1

OncologyHematology

8+59.3+0.1
179CDK7

Oncology

8+59.3-2.0
180AFP

Oncology

7+59.3+0.0
181LILRB4

OncologyHematology

7+59.2+16.0
182Nav1.7

NeurologyOrthopedicsDermatology

16+59.1+13.1
183NET

Neurology

27+59.0-1.5
184TLR2

Oncology

9+59.0-2.5
185GSPT1

Oncology

7+58.9-0.3
186CD40L

EndocrinologyImmunologyNephrology

10+58.8+0.3
187CD44

Oncology

9+58.8+6.3
188H1 receptor

NeurologyPsychiatry

16+58.7+1.1
189MAT2A

Oncology

7+58.6+12.6
190BAFFR

OncologyHematologyImmunology

9+58.6+18.2
191TNF-alpha

PulmonologyEndocrinologyInfectious disease

17+58.4-0.1
192IL-4R

Oncology

10+58.3+16.7
193RIPK1

GastroenterologyHematology

8+58.3+0.2
194PDE5

NeurologyCardiovascular

10+57.9+2.9
195HDAC3

Oncology

9+57.8+0.5
196IL-2RG

Oncology

7+56.7+0.1
197MC4R

EndocrinologyNeurology

11+56.7+2.1
198IL-18

DermatologyGastroenterologyImmunology

8+56.5-0.7
199IL-7R

DermatologyInfectious diseaseOncology

7+56.4+5.7
200MR

Cardiovascular

11+56.4+4.6

Source: Convoke pipeline data · snapshot 2026-11-11.

Overall, overheated targets concentrate in oncology and hematology. This is expected, oncology has been fiercely competitive for years. Familiar targets like PD-1, EGFR, HER2, VEGF, and BTK rank highly and remain crowded with later-generation follow-ons and bi- and trispecific approaches, ivonescimab, a PD-1 × VEGF bispecific being among the most notable. CD3's position at the top of list reflects its use as the preferred T-cell surface antigen in multispecific T-cell engagers.

Topoisomerase I is an older chemotherapy target, but its crowded pipeline reflects the ADC surge and convergence on Topo1-inhibitor payloads (e.g., deruxtecan) following Enhertu's clinical success.

Not all this activity follows an established success. MSLN and CD47 remain popular despite a difficult clinical record. The mesothelin-directed ADC anetumab ravtansine did not improve progression-free survival over vinorelbine in mesothelioma, and Gilead stopped magrolimab development in hematologic cancers after multiple failures. Yet MSLN and CD47 have 40 and 35 active drugs, respectively, and some developers remain optimistic that a different construct, modality or treatment context can overcome earlier limitations.

CD19 and BCMA’s high rankings are a continuation of the long trend of cancer targets gradually moving over to immunology, and in particular the new wave of CAR-T-based cell-depletion strategies (kicked off by promising early results). About 68% of the CD19 drugs are being developed for immunology indiations, and the majority of these (57%) are CAR-Ts. For BCMA, 48% of the drugs are being developed in immunology. These overlapping counts support an autoimmunity-led explanation for much of CD19’s heat: companies are trying to turn B-cell depletion into a durable immune reset.

Beyond oncology, GLP-1R remains hot as obesity development expands into adjacent indications and combination approaches. JAK1 and S1P1 also rank highly, with activity spanning dermatology, immunology and neurology.

Which targets have heated up over the last year?

RankTargetΔ heat (pts)What’s driving the increase
1LTBR+55.6

FAP × LTBR bispecifics aim to build immune-cell hubs inside tumors

2CD56+52.3

CD56-targeted ADCs such as DXC006 and NK-cell products expand the cohort

3INHBE+52.2

An expanding obesity RNAi race: reducing fat while preserving muscle, with potential use alongside incretin drugs

4PACAP+51.5

New anti-PACAP antibodies, including SLTE-1009, expand migraine prevention beyond CGRP

5IL-31RA+46.4

New IL-13 × IL-31R bispecifics target both inflammation and itch

6MRGPRX2+40.9

MRGPRX2 antagonists expand investigation of mast-cell and sensory-neuron signaling across inflammatory diseases and migraine

7CRF2R+39.3

Urocortin-2 analogs such as HM17321 bring CRF2 signaling into obesity and body-composition development

8CD18+38.2

TB511 binds activated CD18 on tumor-associated macrophages and delivers a cell-killing peptide, aiming to remove immune-suppressive cells from solid tumors

9ActRIIB+38.1

Obesity combinations aimed at losing fat while preserving or building muscle

10IL-25+36.6

Investigational anti-IL-25 antibodies such as XKH001 target type 2 inflammatory signaling

Source: Convoke pipeline data · snapshot 2026-11-11.

Next-generation obesity targets like INHBE and ALK7 are fast risers; for instance, Arrowhead has RNAi programs directed against both INHBE and ALK7 in the clinic. An established market for GLP-1s is pulling development into adjacent biology before those approaches are comparably validated. While GLP-1s are already highly effective and unlikely to be displaced, these novel targets are bets that metabolism and body composition can be sculpted in a manner that is complementary to GLP-1 use.

Oncology accounts for several other large increases in target heat. While CD56 and CD18 rose from a low base, others like ALPP and integrin beta 6 are significant risers within the top 200. ALPP's rise has been driven by new engineered T-cell therapies and a T-cell engager. Integrin beta 6 by a rise in ADCs including sigvotatug vedotin and other Pfizer candidates. Another theme in the past year is tumor microenvironment modulation such as PLT012’s attempt to alter lipid-driven immunosuppression in the tumor microenvironment and MST-0312’s approach to stimulating local antitumor immunity through LTBR activation.

What targets are potentially underhyped?

Negative or low heat scores point to targets where the clinical pipeline is smaller relative to the level of validation estimated by our model. Often, it's clear why companies haven't pursued these targets: small markets, delivery problems, uncertain biology, safety concerns and difficult endpoints are common issues. Yet there are interesting targets in this batch that seem plausibly underhyped. We pick out a few molecules below to show some of these low heat targets that seem interesting.

Selected phase 2 or later programs for targets with low heat scores

TargetHeat scoreProgram, developer and stageNotes
KIR3DL2−84.7Lacutamab — Innate/Sobi Phase 2 completed in cutaneous T-cell lymphomaA relatively selective marker on malignant T cells, providing a direct depletion strategy
LEPR−81.7Mibavademab — Regeneron Phase 3 in monogenic obesityReceptor agonism can replace missing leptin signaling in patients with leptin deficiency or dysregulation
DMPK−79.7DYNE-101 — Dyne Phase 3 HARMONIA in myotonic dystrophy type 1Uses a transferrin-receptor-binding antibody fragment to deliver an antisense oligonucleotide into muscle, reducing toxic DMPK RNA and releasing the splicing proteins it traps
CCR9−67.3AZD7798 — AstraZeneca Phase 2 AMALTHEA in Crohn’s diseaseDepletes gut-homing CCR9-positive T cells, potentially removing pathogenic immune memory
FKRP−65.4BBP-418 — BridgeBio Phase 3; under FDA review for FKRP-related limb-girdle muscular dystrophySupplies substrate to a partially functioning enzyme, restoring downstream protein glycosylation
TNIK−65.4Rentosertib — Insilico Published randomized Phase 2a; advanced to Phase 3 in IPFA distinct approach to fibrotic signaling, with an early lung-function signal
UBE3A-ATS / SNHG14 locus−61.1Obudanersen/ION582 — Ionis Phase 3 REVEAL in Angelman syndromeSuppresses the antisense transcript that silences paternal UBE3A, potentially restoring the missing protein
OTC−54.6ARCT-810 — Arcturus Phase 2 completed in OTC deficiencymRNA replacement addresses the missing urea-cycle enzyme directly
SMURF1−37.1LTP001 — Novartis Phase 2 development, including an integrated Phase 1/2 study in PAHAims to rebalance BMP signaling involved in pulmonary vascular remodeling
CIDEB−35.0ALN-CIDEB — Regeneron/Alnylam Recruiting Phase 2 in MASHHuman loss-of-function genetics supports reducing CIDEB activity to protect against liver disease
MuSK−24.9Adimanebart/ARGX-119 — argenx Phase 2 SPARKLE in spinal muscular atrophyStrengthens neuromuscular-junction signaling, potentially complementing therapies that restore SMN expression
Kv7.3−11.7Azetukalner — Xenon Positive Phase 3; NDA submitted for focal seizuresOpening Kv7.2/7.3 channels reduces neuronal hyperexcitability. In Phase 3 X-TOLE2, 25 mg azetukalner produced a 53.2% median reduction in monthly focal seizure frequency versus 10.4% with placebo over 12 weeks

Source: Convoke pipeline data · snapshot 2026-11-11.

Conclusion

If we zoom out and look at macro trends, we see a clear tendency toward increased target crowding over time. Novel targets account for a decreasing share of new clinical drugs: 13.5% in 2015, versus 6.4% in 2025. About 6.1% of new drugs entering the clinic are going after targets that haven't been tested clinically before, and ~58% are going after targets with an approved drug.

Explore versus exploit

Most new clinical drugs revisit previously explored targets

First clinical drug entries by target precedent · All areasShare of new clinical drugs0%25%50%75%100%2005 · At least one first-time clinical target: 77 (29%)2005 · Previously explored, no prior regulatory approval: 103 (38%)2005 · Target with prior regulatory approval: 89 (33%)20052006 · At least one first-time clinical target: 72 (24%)2006 · Previously explored, no prior regulatory approval: 106 (36%)2006 · Target with prior regulatory approval: 116 (39%)2007 · At least one first-time clinical target: 62 (19%)2007 · Previously explored, no prior regulatory approval: 142 (43%)2007 · Target with prior regulatory approval: 129 (39%)2008 · At least one first-time clinical target: 80 (24%)2008 · Previously explored, no prior regulatory approval: 130 (38%)2008 · Target with prior regulatory approval: 129 (38%)2009 · At least one first-time clinical target: 59 (18%)2009 · Previously explored, no prior regulatory approval: 131 (41%)2009 · Target with prior regulatory approval: 133 (41%)2010 · At least one first-time clinical target: 42 (13%)2010 · Previously explored, no prior regulatory approval: 157 (50%)2010 · Target with prior regulatory approval: 116 (37%)20102011 · At least one first-time clinical target: 62 (19%)2011 · Previously explored, no prior regulatory approval: 142 (43%)2011 · Target with prior regulatory approval: 127 (38%)2012 · At least one first-time clinical target: 40 (15%)2012 · Previously explored, no prior regulatory approval: 111 (42%)2012 · Target with prior regulatory approval: 113 (43%)2013 · At least one first-time clinical target: 47 (17%)2013 · Previously explored, no prior regulatory approval: 109 (40%)2013 · Target with prior regulatory approval: 114 (42%)2014 · At least one first-time clinical target: 67 (21%)2014 · Previously explored, no prior regulatory approval: 97 (30%)2014 · Target with prior regulatory approval: 156 (49%)2015 · At least one first-time clinical target: 47 (14%)2015 · Previously explored, no prior regulatory approval: 152 (44%)2015 · Target with prior regulatory approval: 149 (43%)20152016 · At least one first-time clinical target: 57 (15%)2016 · Previously explored, no prior regulatory approval: 142 (38%)2016 · Target with prior regulatory approval: 170 (46%)2017 · At least one first-time clinical target: 49 (11%)2017 · Previously explored, no prior regulatory approval: 156 (35%)2017 · Target with prior regulatory approval: 236 (54%)2018 · At least one first-time clinical target: 55 (11%)2018 · Previously explored, no prior regulatory approval: 171 (34%)2018 · Target with prior regulatory approval: 281 (55%)2019 · At least one first-time clinical target: 59 (12%)2019 · Previously explored, no prior regulatory approval: 212 (42%)2019 · Target with prior regulatory approval: 234 (46%)2020 · At least one first-time clinical target: 76 (13%)2020 · Previously explored, no prior regulatory approval: 221 (37%)2020 · Target with prior regulatory approval: 296 (50%)20202021 · At least one first-time clinical target: 64 (9%)2021 · Previously explored, no prior regulatory approval: 257 (37%)2021 · Target with prior regulatory approval: 380 (54%)2022 · At least one first-time clinical target: 60 (8%)2022 · Previously explored, no prior regulatory approval: 283 (39%)2022 · Target with prior regulatory approval: 382 (53%)2023 · At least one first-time clinical target: 60 (8%)2023 · Previously explored, no prior regulatory approval: 296 (39%)2023 · Target with prior regulatory approval: 397 (53%)2024 · At least one first-time clinical target: 46 (6%)2024 · Previously explored, no prior regulatory approval: 279 (38%)2024 · Target with prior regulatory approval: 418 (56%)2025 · At least one first-time clinical target: 47 (6%)2025 · Previously explored, no prior regulatory approval: 262 (35%)2025 · Target with prior regulatory approval: 431 (58%)20252026 · At least one first-time clinical target: 39 (6%)2026 · Previously explored, no prior regulatory approval: 232 (36%)2026 · Target with prior regulatory approval: 367 (58%)638At least one first-time clinical targetPreviously explored, no prior regulatory approvalTarget with prior regulatory approval

Source: Convoke pipeline data · snapshot 2026-11-11.

One interpretation of this trend is that, like the movie industry, new developments are so expensive and risky that it's easier to reboot and remake than to try something genuinely new. Another is that this is mostly an oncology related phenomenon driven by the industry's great push into cancer drugs that started about 20 years ago. While target crowding is a problem in all therapeutic areas, it's mainly a problem in oncology where failure rates and competition are both extremely high. Oncology has had a particularly large expansion in new programs over the past decade: annual clinical entrants increased 2.4-fold in 10 years from 2015 to 2025. Over the same time the first-time-target share fell from 13.1% to 5.8%. We've seen some pullback and rotation into other areas like immunology and neurology in recent years as developers begin to question their return on investment. Perhaps the most pessimistic interpretation is that, in many therapeutic areas, single target biology seems to be mined out. Even targets supported by human genetics have produced major disappointments: Novartis’ pelacarsen lowered Lp(a) but missed its cardiovascular endpoint in Lp(a)HORIZON, and Novo Nordisk’s IL-6 inhibitor ziltivekimab missed its cardiovascular endpoint in ZEUS despite lowering inflammatory markers. Both are particularly striking because of strong genetic support linking Lp(a) and IL-6 receptor signaling to coronary heart disease. While we at Convoke are certain that AI (both LLMs/agentic AI and specialized molecular design models) will increase industry efficiency over a medium-term time horizon, our expectation is that it will increase molecule-design and development capacity faster than it increases the supply of genuinely new, clinically useful target ideas. If that is right, better tools will produce more crowding around the same biology. Faster, cheaper, and more robust human data collection is likely necessary to meaningfully increase the supply of new targets.

Methodology

Targets are usually thought of as being validated or not; it's usually a binary description. However, in the absence of an FDA approval or an unambiguously positive adequately powered clinical trial, how do we say a target is "validated"? Can we say that a target is 20%, or 50%, or 80% validated when we don't know if a drug against that target will eventually be approved? FDA approvals are relatively rare events, and not every target with a drug in the clinic has a historical approval for that target. For our heat index, we wanted a score that captured some measure of confidence in validation for a target, or 'progress toward validation' even without an FDA approval. After some experimentation, we came up with an approach that trained a model to answer this question similar to this one: How much does the pattern of development (incl. number of drugs by stage and failure rates) in this target–indication pair (for example, TNF in Rheumatoid arthritis) look like indication–target pairs with a recorded FDA approval in our drug program database?

We used a random forest (RF), a collection of decision trees that each learn small rules about which evidence patterns tend to accompany FDA approvals. Each tree in the forest estimates the frequency of approval-bearing examples in the group a target–indication pair falls into. Random forest models are nice because they are relatively easy to interpret and are simple to implement and train. Specifically, we hid information on whether or not a drug was approved and trained the RF model to predict whether or not there is currently an approved drug for each target–indication pair.

Example single decision tree in the random forest

A simplified view of fitted tree 79Ask whether at least two programs reached Phase 3. If no, ask whether any reached Phase 2. If yes, ask whether there are at least five clinical programs. TSLP follows yes, then yes. The four groups have recorded approval frequencies of 4.1%, 15.1%, 51.5%, 80.3%. Deeper branches are collapsed.NoYesNo4.1%approval frequencyYes15.1%approval frequencyNo51.5%approval frequencyYes80.3%approval frequency2+ Phase 3 programsrecorded?1+ Phase 2+ programsrecorded?5+ clinical programsrecorded?

Real splits from tree 79 of the saved model; deeper branches are collapsed. Percentages show recorded approval-label frequencies within these groups. The full forest continues splitting, averages 160 tree estimates, then calibrates the result. Its score for TSLP × asthma is 94.4%.

Source: Convoke pipeline data · snapshot 2026-11-11.

Even though this model isn't intended as a biological simulator (its training objective is too narrow and features too simplistic and prone to leakage for that), some recognizable biological understanding does emerge. A basic check is whether the model puts familiar mechanisms near the top in well-studied diseases. The examples below use the same saved forest and show the five highest-scoring targets in each indication. Diabetes, rheumatoid arthritis and asthma each bring recognizable targets to the top; we can then ask how that evidence develops over time.

Model predicted target validation scores for 3 example indications

Rank

Type 2 diabetes

Rheumatoid arthritis

Asthma

1DPP4100.0%TNF-alpha99.9%ADRB2100.0%
2GLP-1R100.0%IL-6R99.2%GR99.5%
3INSR100.0%COX-299.1%IL-597.0%
4SGLT299.9%JAK191.0%M3 receptor95.0%
5PPARgamma99.5%IL-17A84.1%TSLP94.4%

Source: Convoke pipeline data · snapshot 2026-11-11.

To increase the sample and look at temporal trends, we reconstruct annual pipelines back to 2000, giving the model earlier and sparser views of the evidence. If we look at the validation over time with an example, e.g., TSLP in asthma, we can see that as evidence accumulated and programs advanced our simple model got more confident in the level of validation.

TSLP’s validation score rises as asthma evidence accumulates

Reconstructed annual RF validation scores for TSLP in asthmaModeled validationRF approval-recovery score0%25%50%75%100%2010201520202025TSLP × Asthma · 2011: 2.8% · 1 dated clinical programs, 0 reached P2+ and 0 reached P3TSLP × Asthma · 2012: 2.8% · 1 dated clinical programs, 0 reached P2+ and 0 reached P3TSLP × Asthma · 2013: 3.9% · 1 dated clinical programs, 1 reached P2+ and 0 reached P3TSLP × Asthma · 2014: 3.9% · 1 dated clinical programs, 1 reached P2+ and 0 reached P3TSLP × Asthma · 2015: 3.8% · 1 dated clinical programs, 1 reached P2+ and 0 reached P3TSLP × Asthma · 2016: 3.8% · 1 dated clinical programs, 1 reached P2+ and 0 reached P3TSLP × Asthma · 2017: 36.3% · 2 dated clinical programs, 1 reached P2+ and 1 reached P3TSLP × Asthma · 2018: 36.3% · 2 dated clinical programs, 1 reached P2+ and 1 reached P3TSLP × Asthma · 2019: 35.0% · 2 dated clinical programs, 1 reached P2+ and 1 reached P3TSLP × Asthma · 2020: 34.6% · 2 dated clinical programs, 2 reached P2+ and 1 reached P3TSLP × Asthma · 2021: 36.3% · 6 dated clinical programs, 2 reached P2+ and 1 reached P3TSLP × Asthma · 2022: 49.5% · 9 dated clinical programs, 3 reached P2+ and 1 reached P3TSLP × Asthma · 2023: 39.1% · 14 dated clinical programs, 6 reached P2+ and 1 reached P3TSLP × Asthma · 2024: 48.5% · 17 dated clinical programs, 8 reached P2+ and 1 reached P3TSLP × Asthma · 2025: 88.8% · 21 dated clinical programs, 13 reached P2+ and 4 reached P3TSLP × Asthma · 2026: 94.4% · 27 dated clinical programs, 16 reached P2+ and 6 reached P3TSLP · 94.4%AsthmaEvidence available by year-end · 2026 to date

Source: Convoke pipeline data · snapshot 2026-11-11.

Finally, to calculate the heat score (shown in the heat index table), we take a clinical-stage program count-weighted average of its RF predicted validation scores across eligible indications for each target. We then fit a linear regression relating that score to the log of the number of distinct active clinical-stage drugs. Converting the fitted value back into a drug count gives us the expected number of drugs at that level of validation.

The heat score measures how far the actual drug count is above or below that expectation, on a scale from −100 to +100. Zero means as many drugs as expected for the level of evidence. High scores indicate more active clinical drugs than expected given the target’s modeled validation.